SPOTLIGHT -
EP. 1: Introduction: Checkpoint Inhibition in NSCLC
EP. 2: Checkpoint Inhibitor Related Pseudoprogression in NSCLC
EP. 3: Immune Checkpoint Inhibitor Combinations in NSCLC
EP. 4: Current Status of Immunotherapy in NSCLC
EP. 5: Second-Generation ALK Inhibitors in NSCLC
EP. 6: Development of ALK Inhibitors in Advanced NSCLC
EP. 7: Next-Generation Targeted Therapies in NSCLC
EP. 8: Adjuvant EGFR Inhibition in Patients With NSCLC
EP. 9: Optimizing Maintenance Therapy in NSCLC
EP. 10: Maintenance Therapy in Non-Small Cell Lung Cancer
EP. 11: Determining When to Administer Maintenance Therapy in NSCLC
EP. 12: Next-Generation Sequencing in Lung Cancer
EP. 13: Skeletal-Related Event Management in Lung Cancer
EP. 14: Final Thoughts on Improving Outcomes in NSCLC
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
